98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1051/medsci/20122811005 | DOI Listing |
Managing diabetes in older adults requires balancing long-term glycaemic control with the prevention of hypoglycaemia, to which this population is particularly vulnerable owing to frailty, multimorbidity and cognitive decline. Guidelines recommend individualized glucose targets for older adults, particularly those with multimorbidity or increased hypoglycaemia risk. For individuals with frailty or cognitive impairment, relaxed HbA1c targets are often appropriate to reduce the risk of adverse events.
View Article and Find Full Text PDFJ Drug Target
September 2025
Department of Pharmacology, Rajarshi Shahu College of Pharmacy, Buldana, Maharashtra, INDIA.
Natural phytoconstituents such as betanin and curcumin have attracted interest for their significant antioxidant and anti-inflammatory properties. Their therapeutic efficacy is notably constrained by inadequate bioavailability and reduced skin permeability. The current study developed an ethosome-based gel system for the delivery of betanin and curcumin, with the objective of improving transdermal penetration and providing sustained anti-inflammatory effects.
View Article and Find Full Text PDFJ Mater Chem B
September 2025
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Oral Prosthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China.
Infected wound treatment remains a critical challenge in clinical medicine. Although existing treatments, like local debridement, antimicrobial agents, and growth factor therapies, have demonstrated certain therapeutic effects, they primarily target only specific stages of wound healing. Moreover, the escalating issue of antibiotic resistance limits their efficacy.
View Article and Find Full Text PDFCirculation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDF